NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials

SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.

Spinal cord nerve energy impulses into brain
• Source: shutterstock.com

Nevro expects new results from two randomized trials will help it bring its HF10 spinal cord stimulation (SCS) therapy to hundreds of thousands of patients whose pain is not adequately treated with medical therapy.

Nevro markets the Senza systems that deliver its HF10 therapy, a proprietary 10 kHz waveform developed to treat chronic pain....

More from Clinical Trials

More from R&D